← back to search

Anton Wellstein

Georgetown University · US
Area of research
Molecular Biology · Cell Biology
Research interest
Research interests include Proteoglycans and glycosaminoglycans research, Fibroblast Growth Factor Research, Estrogen and related hormone effects, and HER2/EGFR in Cancer Research.
h-index
59
citations
12,010
works
389
NIH funding
primary concept
Medicine
email

Recent publications

Chemotherapy-Induced Sperm RNAs Disrupt Embryogenesis and Underlie Reproductive Outcomes in a Pre-Clinical Model of Childhood Cancer Survivors
2026cited by 0position: contributordoi
Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines.
2025cited by 10position: contributordoi
Circulating cell-free DNA methylation patterns indicate cellular sources of allograft injury after liver transplant.
2025cited by 4position: contributordoi
Targeting TEAD in cancer.
2025cited by 3position: contributordoi
Differential Effects of IL4I1 Protein on Lymphocytes From Healthy and Multiple Sclerosis Patients.
2025cited by 0position: contributordoi
Senescence Inducers and Senolytics – Pathways and Drugs Targeting Cellular Senescence
2025cited by 0position: contributordoi
TEAD inhibition alters the lung immune microenvironment and attenuates metastasis
2025cited by 0position: contributordoi
A pancreatic cancer organoid-in-matrix platform shows distinct sensitivities to T cell killing.
2024cited by 10position: contributordoi
The Role of Aging and Senescence in Immune Checkpoint Inhibitor Response and Toxicity.
2024cited by 7position: contributordoi
Tumor specimen cold ischemia time impacts molecular cancer drug target discovery.
2024cited by 5position: contributordoi
The Role of Aging and Senescence in Immune Checkpoint Inhibitor Response and Toxicity
2024cited by 3position: contributordoi
The Role of Aging and Senescence in Immune Checkpoint Inhibitor Response and Toxicity
2024cited by 0position: contributordoi
Circulating, cell-free methylated DNA indicates cellular sources of allograft injury after liver transplant
2024cited by 0position: contributordoi
Circulating cell-free methylated DNA reveals tissue-specific, cellular damage from radiation treatment
JCI Insight 2023cited by 16position: lastdoi
Pleiotrophin drives a prometastatic immune niche in breast cancer.
2023cited by 16position: contributordoi
Stromal Senescence following Treatment with the CDK4/6 Inhibitor Palbociclib Alters the Lung Metastatic Niche and Increases Metastasis of Drug-Resistant Mammary Cancer Cells.
2023cited by 15position: contributordoi
AIB1/SRC-3/NCOA3 function in estrogen receptor alpha positive breast cancer.
2023cited by 14position: contributordoi
Circulating cell-free methylated DNA reveals tissue-specific, cellular damage from radiation treatment.
2023cited by 14position: contributordoi
Loss of ANCO1 Expression Regulates Chromatin Accessibility and Drives Progression of Early-Stage Triple-Negative Breast Cancer.
2023cited by 5position: contributordoi
Subpopulations of AIB1 isoform-expressing breast cancer cells enable invasion and metastasis.
2023cited by 1position: contributordoi
Figure S1 from An AIB1 Isoform Alters Enhancer Access and Enables Progression of Early-Stage Triple-Negative Breast Cancer
2023cited by 0position: contributordoi
Supplemental Figure 6 from Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
2023cited by 0position: contributordoi
Supplementary Methods from Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
2023cited by 0position: contributordoi
Supplemental Figure 3 from Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
2023cited by 0position: contributordoi
Supplemental Figure 6 from Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
2023cited by 0position: contributordoi
Table S1 from An AIB1 Isoform Alters Enhancer Access and Enables Progression of Early-Stage Triple-Negative Breast Cancer
2023cited by 0position: contributordoi
Figure S5 from An AIB1 Isoform Alters Enhancer Access and Enables Progression of Early-Stage Triple-Negative Breast Cancer
2023cited by 0position: contributordoi
Table S2 from An AIB1 Isoform Alters Enhancer Access and Enables Progression of Early-Stage Triple-Negative Breast Cancer
2023cited by 0position: contributordoi
Data from Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
2023cited by 0position: contributordoi
Supplemental Figure 7 from Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 60 papers (2019–2026)Garrett T. Graham · Cornell University43 papers (2019–2023)Marcel O. Schmidt · Georgetown University32 papers (2021–2025)Moray J. Campbell · Cedars-Sinai Medical Center21 papers (2021–2023)Sidharth Jain · Georgetown Lombardi Comprehensive Cancer Center7 papers (2021–2024)Christopher S. Wilcox · MedStar Georgetown University Hospital6 papers (2012–2020)Anna T. Riegel · Georgetown University Medical Center6 papers (2020–2025)Amber J. Kiliti · Georgetown University6 papers (2022–2025)En Yin Lai · Humboldt-Universität zu Berlin4 papers (2012–2020)Megan E. Barefoot · Georgetown University4 papers (2022–2025)Zaiming Luo · Georgetown University3 papers (2012–2018)Ghada M Sharif · Elsevier, Inc.3 papers (2023–2025)Ivana Peran · 3 papers (2019–2022)Anne Deslattes Mays · Eunice Kennedy Shriver National Institute of Child Health and Human Development3 papers (2019–2022)Tommy Kaplan · Jerusalem University College3 papers (2021–2023)Marcel O. Schmidt · Georgetown University3 papers (2018–2023)William J. Welch · University of British Columbia3 papers (2012–2018)Anna T. Riegel · Georgetown University2 papers (2018–2023)Amber J. Kiliti · Georgetown University2 papers (2021–2023)Lingli Li · Georgetown University2 papers (2018–2020)